Pallagi-Kunstár, Éva <br/><br/>
Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.  [electronic resource] 

 -  World journal of gastroenterology  May 2014 
 - 5031-5 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2219-2840 
<br/><br/><label>Standard No.: </label>10.3748/wjg.v20.i17.5031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Anti-Inflammatory Agents--adverse effects<br/>Antibodies--blood<br/>Antibodies, Monoclonal--adverse effects<br/>Biomarkers--blood<br/>Case-Control Studies<br/>Drug Hypersensitivity--blood<br/>Drug Monitoring<br/>Female<br/>Humans<br/>Inflammatory Bowel Diseases--blood<br/>Infliximab<br/>Male<br/>Middle Aged<br/>Predictive Value of Tests<br/>Prospective Studies<br/>Remission Induction<br/>Risk Factors<br/>Treatment Failure<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>Young Adult